Orkla Asa (OTCMKTS:ORKLY – Get Free Report) saw strong trading volume on Thursday . Approximately 95,187 shares traded hands during trading, an increase of 31% from the previous session’s volume of 72,844 shares.The stock last traded at $9.9440 and had previously closed at $9.8550.
Analysts Set New Price Targets
Separately, UBS Group downgraded shares of Orkla Asa from a “hold” rating to a “strong sell” rating in a research note on Friday, May 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce”.
Check Out Our Latest Stock Report on ORKLY
Orkla Asa Stock Performance
Orkla Asa (OTCMKTS:ORKLY – Get Free Report) last released its quarterly earnings data on Thursday, August 20th. The company reported $0.17 earnings per share for the quarter, meeting the consensus estimate of $0.17. Orkla Asa had a return on equity of 13.85% and a net margin of 9.63%.The firm had revenue of $1.79 billion during the quarter, compared to the consensus estimate of $1.86 billion.
Orkla Asa Company Profile
Orkla ASA is a Norway-based branded consumer goods company and investment group headquartered in Oslo. The company develops, markets and sells everyday products through a portfolio of businesses serving consumers and professional customers primarily in the Nordic and Baltic countries, as well as selected markets in Europe and other regions.
Orkla’s activities span food and beverages, confectionery and snacks, food ingredients, personal care, health products and household goods. Its portfolio includes a range of local and international brands distributed through grocery stores, specialty retailers, food-service channels and other sales outlets.
Further Reading
- Five stocks we like better than Orkla Asa
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Orkla Asa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orkla Asa and related companies with MarketBeat.com's FREE daily email newsletter.
